House GOP Offers Alternative to Democratic Drug-Pricing Plan (1)

Bloomberg Government subscribers get the stories like this first. Act now and gain unlimited access to everything you need to know. Learn more.

House Republican leaders are offering drug-pricing legislation that they say could become law quickly, laying down a marker for what measures many party members could support ahead of a planned vote on a Democratic drug bill later this week.

The package, unveiled Monday, would create a $3,100 out-of-pocket cap in Medicare’s prescription drug benefit program. It would also take steps to spur new generic drugs and includes a laundry list of changes to Medicare and Medicaid. The legislation includes more than 40 provisions that Democrats and Republicans have previously agreed to support, Republicans say.

(Andrew Harrer/Bloomberg)
Oregon Republican Greg Walden

Greg Walden (R-Ore.), the ranking member of the House Energy and Commerce Committee, called the bill a “solid alternative” to H.R. 3, the Medciare drug-price negotiation bill sponsored by committee Chairman Frank Pallone (D-N.J.) and backed by House Speaker Nancy Pelosi (D-Calif.) .

“Every single provision in the alternative is bipartisan: it could actually become law,” Walden said.

However, Walden did not name any Democrats who are sponsoring his alternative.

Republicans plan to ask for a vote on their legislation as a replacement for the Pelosi-backed bill this week. Walden said he’ll make the case during a Tuesday House Rules Committee meeting.

Rep. Kevin Brady (R-Texas), ranking member of the House Ways and Means Committee, said Republicans are working with the White House and Senate leaders to build support for the legislation.

The proposal comes the same week as a House vote is planned on the Democratic drug-pricing bill, which goes further on using the power of the federal government to force drug manufacturers to lower their prices. That bill isn’t expected to win Senate passage.

Caps Left Off

The House Republican bill, slated to be numbered H.R. 19, hews closely to bipartisan legislation from Senate Finance Committee Chairman Chuck Grassley (R-Iowa) and ranking member Ron Wyden (D-Ore.), but without that bill’s caps on price increases for drugs in Medicare.

Those caps have proven divisive among congressional Republicans. Most Republicans on the Finance Committee opposed the package in a vote earlier this year, largely because of the inflation caps.

Democrats such as Wyden have said they want any major drug-pricing package to include some kind of mechanism, such as caps, for limiting increases on drug prices.

Republicans say drug prices can instead be lowered by paving the way for the creation of low-cost generic drugs. Monday’s House GOP package would take on some abuses by brand-name drugmakers to prevent generics from coming to the market.

To contact the reporter on this story: Alex Ruoff in Washington at

To contact the editors responsible for this story: Paul Hendrie at; Jonathan Nicholson at; Robin Meszoly at

Stay informed with more news like this – from the largest team of reporters on Capitol Hill – subscribe to Bloomberg Government today. Learn more.